Theravance Biopharma, Inc.

NasdaqGM:TBPH 주식 보고서

시가총액: US$413.9m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Theravance Biopharma 관리

관리 기준 확인 3/4

Theravance Biopharma's CEO는 Rick Winningham, Jun2014 에 임명되었습니다 의 임기는 10.92 년입니다. 총 연간 보상은 $ 4.32M, 24.3% 로 구성됩니다. 24.3% 급여 및 75.7% 보너스(회사 주식 및 옵션 포함). 는 $ 16.39M 가치에 해당하는 회사 주식의 3.97% 직접 소유합니다. 16.39M. 경영진과 이사회의 평균 재임 기간은 각각 2 년과 6.3 년입니다.

주요 정보

Rick Winningham

최고 경영자

US$4.3m

총 보상

CEO 급여 비율24.3%
CEO 임기10.1yrs
CEO 소유권4.0%
경영진 평균 재임 기간2.1yrs
이사회 평균 재임 기간6.4yrs

최근 관리 업데이트

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Recent updates

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

Theravance Biopharma EPS misses by $0.16, misses on revenue

May 04

Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Apr 21
Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

CEO 보상 분석

Rick Winningham 의 보수는 Theravance Biopharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$45m

Dec 31 2023US$4mUS$1m

-US$55m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$75m

Dec 31 2022US$6mUS$1m

-US$93m

Sep 30 2022n/an/a

-US$136m

Jun 30 2022n/an/a

-US$196m

Mar 31 2022n/an/a

-US$226m

Dec 31 2021US$4mUS$1m

-US$265m

Sep 30 2021n/an/a

-US$266m

Jun 30 2021n/an/a

-US$264m

Mar 31 2021n/an/a

-US$275m

Dec 31 2020US$7mUS$1m

-US$295m

Sep 30 2020n/an/a

-US$285m

Jun 30 2020n/an/a

-US$270m

Mar 31 2020n/an/a

-US$247m

Dec 31 2019US$6mUS$984k

-US$236m

Sep 30 2019n/an/a

-US$221m

Jun 30 2019n/an/a

-US$222m

Mar 31 2019n/an/a

-US$223m

Dec 31 2018US$3mUS$957k

-US$216m

Sep 30 2018n/an/a

-US$252m

Jun 30 2018n/an/a

-US$260m

Mar 31 2018n/an/a

-US$285m

Dec 31 2017US$2mUS$933k

-US$285m

보상 대 시장: Rick 의 총 보상 ($USD 4.32M )은 US 시장( $USD 2.46M ).

보상과 수익: Rick 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Rick Winningham (64 yo)

10.1yrs

테뉴어

US$4,318,531

보상

Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022 . He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Compa...

리더십 팀

이름위치테뉴어보상소유권
Rick Winningham
Chairman & CEO10.1yrsUS$4.32m3.97%
$ 16.5m
Aziz Sawaf
Senior VP & CFO1.5yrsUS$1.39m0.68%
$ 2.8m
Stuart Knight
Senior VP of IT&I and Chief Information Officerno data데이터 없음데이터 없음
Gail Cohen
Vice President of Corporate Communications & Investor Relationsno data데이터 없음데이터 없음
Brett Grimaud
Senior VP2.1yrs데이터 없음0.72%
$ 3.0m
Rhonda Farnum
Chief Business Officer and Senior VP of Commercial & Medical Affairs2.6yrsUS$942.81k0.70%
$ 2.9m
Stacy Pryce
Senior VP & Chief Strategy Officer1.8yrs데이터 없음데이터 없음
Aine Miller
SVP of Dev.no data데이터 없음0.34%
$ 1.4m

2.1yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: TBPH 의 관리팀은 경험 ( 2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Rick Winningham
Chairman & CEO11yrsUS$4.32m3.97%
$ 16.5m
Eran Broshy
Independent Director10.1yrsUS$205.14k0.14%
$ 595.8k
Deepika Pakianathan
Independent Director4yrsUS$207.68k0.098%
$ 403.5k
Dean Mitchell
Lead Independent Director10.1yrsUS$211.73k0.17%
$ 685.5k
James Kelly
Independent Director1.3yrsUS$43.10k데이터 없음
Donal O'Connor
Independent Director8.8yrsUS$195.80k0.13%
$ 540.8k
Susannah Gray
Independent Director1.4yrsUS$346.47k0.065%
$ 268.0k
Laurie Smaldone Alsup
Independent Director6.4yrsUS$197.68k0.13%
$ 547.5k
Jeremy Grant
Independent Directorless than a yearUS$168.36k0.046%
$ 189.8k

6.4yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: TBPH 의 이사회는 경험(평균 재직 기간 6.3 년)으로 간주됩니다.